Tyrosine kinase receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 18: Line 18:
TRK-A contains an extracellular ligand binding domain (LBD), a transmembrane helix and an intracellular region which contains the kinase domain. The kinase domain (PDB code [[4yne]]) contains the tripeptide DFG which flips out in TRK-A inactivated form. <scene name='83/839914/Cv/3'>Inhibitor binding site</scene> (PDB code [[4yne]]). Water molecules are shown as red spheres. The structure of the complex of TRK-A with the phenylpyrrolidine derivative shows the inhibitor forming hydrogen bonds to Met620 and Lys572 residues and π-π interactions of it with Phe617 and Phe 698 <ref>PMID:26005534</ref>.
TRK-A contains an extracellular ligand binding domain (LBD), a transmembrane helix and an intracellular region which contains the kinase domain. The kinase domain (PDB code [[4yne]]) contains the tripeptide DFG which flips out in TRK-A inactivated form. <scene name='83/839914/Cv/3'>Inhibitor binding site</scene> (PDB code [[4yne]]). Water molecules are shown as red spheres. The structure of the complex of TRK-A with the phenylpyrrolidine derivative shows the inhibitor forming hydrogen bonds to Met620 and Lys572 residues and π-π interactions of it with Phe617 and Phe 698 <ref>PMID:26005534</ref>.
-
The extracellular domain of TRK-A contains 3 Leu-rich regions flanked by 2 Cys-rich regions, 2 immunoglobulin-like domains and the nerve growth factor (NGF) binding domain. The complex between TRK-A and the nerve growth factor (PDB code [[2igf]]} is a 2:2 dimer. The C-terminal immunoglobulin-like domain interacts with the NGF<ref>PMID:17196528</ref>.
+
The extracellular domain of TRK-A contains 3 Leu-rich regions flanked by 2 Cys-rich regions, 2 immunoglobulin-like domains and the nerve growth factor (NGF) binding domain. The complex between TRK-A and the nerve growth factor (PDB code [[2igf]]} is a 2:2 dimer. The C-terminal immunoglobulin-like domain interacts with the NGF<ref>PMID:17196528</ref>.
</StructureSection>
</StructureSection>

Revision as of 08:49, 2 April 2020

Human TRK-A kinase domain complex with inhibitor, MPD and sulfate (PDB code 6p11)

Drag the structure with the mouse to rotate

3D Structures tyrosine kinase receptor

Updated on 02-April-2020

References

  1. ↑ Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. PMID:29455648 doi:http://dx.doi.org/10.1186/s12943-018-0782-4
  2. ↑ Deinhardt K, Chao MV. Trk receptors. Handb Exp Pharmacol. 2014;220:103-19. doi: 10.1007/978-3-642-45106-5_5. PMID:24668471 doi:http://dx.doi.org/10.1007/978-3-642-45106-5_5
  3. ↑ Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014, Jan 3. PMID:24390213 doi:http://dx.doi.org/10.1038/modpathol.2013.233
  4. ↑ Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050., eCollection 2015 May 14. PMID:26005534 doi:http://dx.doi.org/10.1021/acsmedchemlett.5b00050
  5. ↑ Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Tyrosine_kinase_receptor"
Personal tools